Concomitant Tumor and Autoantigen Vaccination Supports Renal Cell Carcinoma Rejection

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Immunology

• Publication date

  2010-07-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4049/jimmunol.0902683PMID 20548033
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Dendritic cells for cancer immunotherapy].

  2012cited by this paper
• Cancer immunology.

  2011cited by this paper
• The Efficacy of an IL-1α Vaccine Depends on IL-1RI Availability and Concomitant Myeloid-derived Suppressor Cell Reduction

  2009cited by this paper
• Role of autologous and allogeneic stem cell transplantation in myeloma

  2009cited by this paper
• Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines.

  2009cited by this paper
• Bacterial Antigen Expression Is an Important Component in Inducing an Immune Response to Orally Administered Salmonella-Delivered DNA Vaccines

  2009cited by this paper
• Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy

  2009cited by this paper
• Immunosuppressive networks in the tumour environment and their effect in dendritic cells.

  2009cited by this paper
• Renal cell carcinoma

  2009cited by this paper
• Use of genetically modified bacteria to modulate adaptive immunity.

  2009cited by this paper
• Identifying autoantibody signatures in cancer: a promising challenge

  2009cited by this paper
• Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.

  2009cited by this paper
• Dendritic cells: therapy and imaging

  2009cited by this paper
• Cancer vaccines for established cancer: how to make them better?

  2008cited by this paper
• Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer.

  2008cited by this paper
• Concerted Potent Humoral Immune Responses to Autoantigens Are Associated with Tumor Destruction and Favorable Clinical Outcomes without Autoimmunity

  2008cited by this paper
• Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity

  2008cited by this paper
• Opposing effects of fibrosarcoma cell‐derived IL‐1α and IL‐1β on immune response induction

  2008cited by this paper
• Salmonella type III-mediated heterologous antigen delivery: a versatile oral vaccination strategy to induce cellular immunity against infectious agents and tumors.

  2008cited by this paper
• Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model

  2008cited by this paper
• Vaccine therapy for renal cancer

  2008cited by this paper
• Therapeutic Dendritic Cell Vaccination of Patients With Metastatic Renal Cell Carcinoma: A Clinical Phase 1/2 trial

  2008influential reference
• Heterospecific CD4 Help to Rescue CD8 T Cell Killers1

  2008cited by this paper
• Tumor vaccines in renal cell carcinoma

  2008influential reference
• Dendritic cells in cancer immunotherapy.

  2008cited by this paper
• A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting

  2008cited by this paper
• Cancer Immunology

  2008cited by this paper
• Superior induction of anti‐tumor CTL immunity by extended peptide vaccines involves prolonged, DC‐focused antigen presentation

  2008cited by this paper
• Targeting of Th1-associated chemokine receptors CXCR3 and CCR5 as therapeutic strategy for inflammatory diseases.

  2007cited by this paper
• mRNA-based gene transfer as a tool for gene and cell therapy.

  2007cited by this paper
• Modulation of chemokines by staphylococcal superantigen in atopic dermatitis.

  2007cited by this paper
• Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting

  2007influential reference
• Apoptic Renal Carcinoma Cells are Better Inducers of Cross-Presenting Activity than Their Primary Necrotic Counterpart

  2007cited by this paper
• Modification of the tumor microenvironment to enhance immunity.

  2007cited by this paper
• Dendritic/tumor fusion cell-based vaccination against cancer

  2007cited by this paper
• Immune suppression in renal cell carcinoma.

  2007cited by this paper
• Capture of membrane components via trogocytosis occurs in vivo during both dendritic cells and target cells encounter by CD8+ T cells

  2007cited by this paper
• The reverse proteomics for identification of tumor antigens.

  2007cited by this paper
• Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma.

  2007influential reference
• Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells

  2006cited by this paper
• Augmented induction of CD8+ cytotoxic T‐cell response and antitumour resistance by T helper type 1‐inducing peptide

  2006cited by this paper
• Processing and presentation of tumor antigens and vaccination strategies.

  2006cited by this paper
• Double loading of dendritic cell MHC class I and MHC class II with an AML antigen repertoire enhances correlates of T-cell immunity in vitro via amplification of T-cell help.

  2006cited by this paper
• Role of exosomes in immune regulation

  2006cited by this paper
• A very rapid and simple assay based on trogocytosis to detect and measure specific T and B cell reactivity by flow cytometry

  2006cited by this paper
• Human tumor-derived vs dendritic cell-derived exosomes have distinct biologic roles and molecular profiles

  2006cited by this paper
• Serological analysis of human renal cell carcinoma

  2006influential reference
• Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients.

  2006cited by this paper
• Tumor infiltration by myeloid suppressor cells in response to T cell activation in rat gliomas

  2005cited by this paper
• Identification of tumor-associated autoantigens with SEREX.

  2005cited by this paper
• Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells

  2005cited by this paper
• Improved approach to identify cancer-associated autoantigens.

  2005cited by this paper
• Generation of RAGE‐1 and MAGE‐9 peptide‐specific cytotoxic T‐Lymphocyte lines for transfer in patients with renal cell carcinoma

  2005cited by this paper
• Provision of Granulocyte-Macrophage Colony-Stimulating Factor Converts an Autoimmune Response to a Self-Antigen into an Antitumor Response

  2005influential reference
• Tumor Vaccination by Salmonella typhimurium After Transformation with a Eukaryotic Expression Vector in Mice: Impact of a Salmonella typhimurium Gene Interfering with MHC Class I Presentation

  2005influential reference
• Cell motility: Golgi signalling shapes up to ship out.

  2004cited by this paper
• Cancer immunotherapy with mRNA‐transfected dendritic cells

  2004cited by this paper
• Peptide-based vaccines for cancer immunotherapy

  2004cited by this paper
• CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses

  2003cited by this paper
• Membrane traffic: a glitch in the Golgi matrix.

  2003cited by this paper
• Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R).

  2003cited by this paper
• Autoimmunity seen through the SEREX-scope.

  2003cited by this paper
• The CC chemokine CCL20 and its receptor CCR6.

  2003cited by this paper
• Serological identification of antigens associated with renal cell carcinoma.

  2002cited by this paper
• Gene delivery by attenuated Salmonella typhimurium : Comparing the efficacy of helper versus cytotoxic T cell priming in tumor vaccination

  2001influential reference
• Prophylactic Tumor Vaccination: Comparison of Effector Mechanisms Initiated by Protein Versus DNA Vaccination1

  2001cited by this paper
• Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity

  2001cited by this paper
• Tumour-induced suppression of immune response and its correction

  2001cited by this paper
• Macrophage Inflammatory Protein 3α Is Expressed at Inflamed Epithelial Surfaces and Is the Most Potent Chemokine Known in Attracting Langerhans Cell Precursors

  2000influential reference
• RNA transfected dendritic cells as cancer vaccines.

  2000cited by this paper
• CXCR4: chemokine receptor extraordinaire

  2000cited by this paper
• Novel variant of p230 trans-Golgi network protein identified by serum from Sjögren's syndrome patient.

  2000cited by this paper
• Identification of renal-cell-carcinoma-related cDNA clones by suppression subtractive hybridization

  1999cited by this paper
• The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes.

  1999cited by this paper
• The role of chemokines in the regulation of dendritic cell trafficking

  1999cited by this paper
• A novel Rab6-interacting domain defines a family of Golgi-targeted coiled-coil proteins.

  1999cited by this paper
• Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma.

  1998cited by this paper
• Isolation of Dendritic Cells

  1998cited by this paper
• Isolation of Dendritic Cells

  1998cited by this paper
• Human autoantibodies as reagents to conserved Golgi components. Characterization of a peripheral, 230-kDa compartment-specific Golgi protein.

  1992cited by this paper
• Cross‐blocking studies with monoclonal antibodies against I‐A molecules of haplotypes b, d and k

  1982cited by this paper
• Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines

  1981cited by this paper
• Renal cell carcinoma.

  1956influential reference

• T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma

  2021cites this paper
• In Vitro Assessment of the Expression and T Cell Immunogenicity of the Tumor-Associated Antigens BORIS, MUC1, hTERT, MAGE-A3 and Sp17 in Uterine Cancer

  2016influential citation
• Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy.

  2014cites this paper
• Assessing T-cell responses in anticancer immunotherapy

  2013cites this paper
• Enhancing Whole-Tumor Cell Vaccination by Engaging Innate Immune System Through NY-ESO-1/Dendritic Cell Interactions

  2013cites this paper
• Tumor-Associated Antigens

  2013cites this paper
• Prognostic value of melanoma-associated antigen A9 in renal cell carcinoma

  2013cites this paper
• Vaccines as consolidation therapy for myeloid leukemia

  2011cites this paper
• Vaccination therapy in renal cell carcinoma: current position and future options in metastatic and localized disease

  2011cites this paper